This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

An International Perspective, 1970 to 1993

Michael Kaback, MD; Joyce Lim-Steele, PhD; Deepti Dabholkar; David Brown; Nancy Levy; Karen Zeiger; for the International TSD Data Collection Network

JAMA. 1993;270(19):2307-2315.

Abstract
Objectives.
—To provide an update of the international experience with carrier screening and prenatal diagnosis for Tay-Sachs disease (TSD), to assess the impact of these efforts, and to review the recent developments in DNA technology with application to TSD carrier detection and screening.

Design.
—Through the International TSD Testing, Quality Control, and Data Collection Center, all testing centers in the world were surveyed annually to assess overall experience with carrier testing and prenatal diagnosis. Quality control and laboratory surveillance of testing centers were performed through an annual assessment, using samples provided by the center.

Setting.
—Tay-Sachs disease testing centers around the world.

Participants.
—Nearly 1 million young adults from both Jewish and non-Jewish populations.

Intervention.
—Gene product screening (enzyme testing) and DNA-based mutation analysis (in some populations).

Main Outcome Measure.
—Impact of screening program on disease incidence.

Results.
—Data from all centers in the international TSD network on experience with TSD carrier testing and prenatal diagnosis since 1974 indicated that more than 36 000 heterozygotes were identified and 1056 couples found to be at risk for TSD in their offspring. A total of 2416 pregnancies at increased risk for TSD were monitored by amniocentesis or chorionic villus sampling. A dramatic decrease in the incidence of TSD in the Jewish populations was demonstrated. With both serum and leukocyte proficiency testing, there have been only 16 instances (of 845 cumulative laboratory evaluations) of one or more errors reported by a laboratory since 1983 resulting in nonaccreditation.

Conclusions.
—This analysis represents a prototypic effort in coordinating adult education, carrier testing, and genetic counseling directed toward prospective prevention of a uniformly fatal childhood disease and demonstrates that such an effort can dramatically affect disease incidence.

(JAMA. 1993;270:2307-2315)

Author Affiliations
From the Department of Pediatrics and Reproductive Medicine, University of California, San Diego, and the Children's Hospital and Health Center, San Diego, Calif.

Footnotes
A complete list of the International TSD Data Collection Network appears at the end of this article.

Reprint requests to the Department of Pediatrics and Reproductive Medicine, University of California, San Diego, Children's Hospital and Health Center, 8110 Birmingham Way, San Diego, CA 92123 (Dr Kaback).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Development of Genomic DNA Reference Materials for Genetic Testing of Disorders Common in People of Ashkenazi Jewish Descent
Kalman et al.
J. Mol. Diagn. 2009;11:530-536.
ABSTRACT | FULL TEXT  

Comprehensive Arrayed Primer Extension Array for the Detection of 59 Sequence Variants in 15 Conditions Prevalent Among the (Ashkenazi) Jewish Population
Schrijver et al.
J. Mol. Diagn. 2007;9:228-236.
ABSTRACT | FULL TEXT  

Evaluation of the Risk for Tay-Sachs Disease in Individuals of French Canadian Ancestry Living in New England
Martin et al.
Clin. Chem. 2007;53:392-398.
ABSTRACT | FULL TEXT  

Heterozygote Carrier Testing in High Schools Abroad: What are the Lessons for the U.S.?
Ross
J Law Med Ethics 2006;34:753-764.
 

Ashkenazi Jews and Breast Cancer: The Consequences of Linking Ethnic Identity to Genetic Disease
Brandt-Rauf et al.
AJPH 2006;96:1979-1988.
ABSTRACT | FULL TEXT  

A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students
Barlow-Stewart et al.
J. Med. Genet. 2003;40:e45-45.
FULL TEXT  

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families
Kauff et al.
J. Med. Genet. 2002;39:611-614.
FULL TEXT  

Commentary: Learning in Lambeth-- the South-East London Screening Study revisited
Leeder
Int J Epidemiol 2001;30:944-945.
FULL TEXT  

Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population: The First 1000 Cases at New York University Medical Center, New York, NY
Kronn et al.
Arch Intern Med 1998;158:777-781.
ABSTRACT | FULL TEXT  

Prenatal Genetic Carrier Testing Using Triple Disease Screening
Eng et al.
JAMA 1997;278:1268-1272.
ABSTRACT  

Benign HEXA Mutations, C739T(R247W) and C745T(R249W), Cause beta -Hexosaminidase A Pseudodeficiency by Reducing the alpha -Subunit Protein Levels
Cao et al.
J. Biol. Chem. 1997;272:14975-14982.
ABSTRACT | FULL TEXT  

{beta}-Galactosidase Gene Mutations in Patients With Slowly Progressive GM1 Gangliosidosis
Kaye et al.
J Child Neurol 1997;12:242-247.
ABSTRACT  

GENETICS EVOLVES FROM BASIC SCIENCE TO MEDICAL SPECIALTY
JWatch General 1993;1993:6-6.
FULL TEXT